An association between liraglutide treatment and reduction in excessive daytime sleepiness in obese subjects with type 2 diabetes

BMC Endocrine Disorders

Volumn 15, Issue 1, 2015, Pages

  Gomez Peralta, Fernando ^a   Abreu, Cristina ^a   Castro, Jose Carlos ^a   Alcarria, Elvira ^a   Cruz Bravo, Margarita ^a   Garcia Llorente, Maria Jesús ^a   Albornos, Cristina ^a   Moreno, Concepción ^a   Cepeda, María ^a   Almodóvar, Francisca ^b  

^a HOSPITAL GENERAL DE SEGOVIA   (Spain)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

Author keywords

Abnormal sleep patterns; Excessive daytime sleepiness; Glucagon like peptide 1; Liraglutide; Obesity; Obstructive sleep apnoea; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; CHOLESTEROL; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG EFFICACY; EPWORTH SLEEPINESS SCALE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NECK CIRCUMFERENCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; COMPLICATION; DIABETES MELLITUS, TYPE 2; DISORDERS OF EXCESSIVE SOMNOLENCE; DRUG EFFECTS; EPIDEMIOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; SPAIN;

BLOOD GLUCOSE; BODY MASS INDEX; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DISORDERS OF EXCESSIVE SOMNOLENCE; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; MIDDLE AGED; OBESITY; RETROSPECTIVE STUDIES; SPAIN; TREATMENT OUTCOME;

EID: 84949228514     PISSN: None     EISSN: 14726823     Source Type: Journal    
DOI: 10.1186/s12902-015-0074-6     Document Type: Article

References (34)

1. Littner MR, Kushida C, Wise M, Davila DG, Morgenthaler T, Lee-Chiong T, et al. Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test. Sleep. 2005;28(1):113-21.
2. Epstein LJ, Kristo D, Strollo Jr PJ, Friedman N, Malhotra A, Patil SP, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med. 2009;5(3):263-76.
3. Resnick HE, Redline S, Shahar E, Gilpin A, Newman A, Walter R, et al. Diabetes and sleep disturbances: findings from the Sleep Heart Health Study. Diabetes Care. 2003;26(3):702-9.
4. Kawakami N, Takatsuka N, Shimizu H. Sleep disturbance and onset of type 2 diabetes. Diabetes Care. 2004;27(1):282-3.
5. Gottlieb DJ, Punjabi NM, Newman AB, Resnick HE, Redline S, Baldwin CM, et al. Association of sleep time with diabetes mellitus and impaired glucose tolerance. Arch Intern Med. 2005;165(8):863-7.
6. Tuomilehto H, Peltonen M, Partinen M, Seppa J, Saaristo T, Korpi-Hyovalti E, et al. Sleep duration is associated with an increased risk for the prevalence of type 2 diabetes in middle-aged women - The FIN-D2D survey. Sleep Med. 2008;9(3):221-7.
7. Chaput JP, Despres JP, Bouchard C, Tremblay A. Association of sleep duration with type 2 diabetes and impaired glucose tolerance. Diabetologia. 2007;50(11):2298-304.
8. Dixon JB, Dixon ME, Anderson ML, Schachter L, O'brien PE. Daytime sleepiness in the obese: not as simple as obstructive sleep apnea. Obesity (Silver Spring). 2007;15(10):2504-11.
9. Vgontzas AN, Papanicolaou DA, Bixler EO, Hopper K, Lotsikas A, Lin HM, et al. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab. 2000;85(3):1151-8.
10. Kim NH, Cho NH, Yun CH, Lee SK, Yoon DW, Cho HJ, et al. Association of obstructive sleep apnea and glucose metabolism in subjects with or without obesity. Diabetes Care. 2013;36(12):3909-15.
11. Chasens ER, Korytkowski M, Sereika SM, Burke LE. Effect of poor sleep quality and excessive daytime sleepiness on factors associated with diabetes self-management. Diabetes Educ. 2013;39(1):74-82.
12. Inkster B, Riha RL, Van LL, Williamson R, McLachlan S, Frier BM, et al. Association between excessive daytime sleepiness and severe hypoglycemia in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care. 2013;36(12):4157-9.
13. Fritscher LG, Mottin CC, Canani S, Chatkin JM. Obesity and obstructive sleep apnea-hypopnea syndrome: the impact of bariatric surgery. Obes Surg. 2007;17(1):95-9.
14. Holty JE, Parimi N, Ballesteros M, Blackwell T, Cirangle PT, Jossart GH, et al. Does surgically induced weight loss improve daytime sleepiness? Obes Surg. 2011;21(10):1535-45.
15. Varela JE, Hinojosa MW, Nguyen NT. Resolution of obstructive sleep apnea after laparoscopic gastric bypass. Obes Surg. 2007;17(10):1279-82.
16. Nerfeldt P, Nilsson BY, Mayor L, Udden J, Friberg D. A two-year weight reduction program in obese sleep apnea patients. J Clin Sleep Med. 2010;6(5):479-86.
17. Elbrond B, Jakobsen G, Larsen S, Agerso H, Jensen LB, Rolan P, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care. 2002;25(8):1398-404.
18. Bode B. An overview of the pharmacokinetics, efficacy and safety of liraglutide. Diabetes Res Clin Pract. 2012;97(1):27-42.
19. Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771.
20. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540-5.
21. Drager LF, Genta PR, Pedrosa RP, Nerbass FB, Gonzaga CC, Krieger EM, et al. Characteristics and predictors of obstructive sleep apnea in patients with systemic hypertension. Am J Cardiol. 2010;105(8):1135-9.
22. Balk EM, Moorthy D, Obadan NO, Patel K, Ip S, Chung M, Bannuru RR, Kitsios GD, Sen S, Iovin RC, Gaylor JM, and et al. Diagnosis and Treatment of Obstructive Sleep Apnea in Adults. Comparative Effectiveness Review No. 32. (Prepared by Tufts Evidence-based Practice Center under Contract No. 290-2007-10055-1). In: AHRQ. 2011. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0016344/pdf/PubMedHealth_PMH0016344.pdf. Accessed 17 Apr 2015.
23. Raman R, Gupta A, Venkatesh K, Kulothungan V, Sharma T. Abnormal sleep patterns in subjects with type II diabetes mellitus and its effect on diabetic microangiopathies: Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetic Study (SN-DREAMS, report 20). Acta Diabetol. 2012;49(4):255-61.
24. Liu A, Kushida CA, Reaven GM. Risk for obstructive sleep apnea in obese, nondiabetic adults varies with insulin resistance status. Sleep Breath. 2013;17(1):333-8.
25. Hayley AC, Williams LJ, Kennedy GA, Berk M, Brennan SL, Pasco JA. Excessive daytime sleepiness and metabolic syndrome: a cross-sectional study. Metabolism. 2015;64(2):244-52.
26. Renko AK, Hiltunen L, Laakso M, Rajala U, Keinanen-Kiukaanniemi S. The relationship of glucose tolerance to sleep disorders and daytime sleepiness. Diabetes Res Clin Pract. 2005;67(1):84-91.
27. Basterfield L, Lumley LK, Mathers JC. Wheel running in female C57BL/6J mice: impact of oestrus and dietary fat and effects on sleep and body mass. Int J Obes (Lond). 2009;33(2):212-8.
28. Jenkins JB, Omori T, Guan Z, Vgontzas AN, Bixler EO, Fang J. Sleep is increased in mice with obesity induced by high-fat food. Physiol Behav. 2006;87(2):255-62.
29. Panossian LA, Veasey SC. Daytime sleepiness in obesity: mechanisms beyond obstructive sleep apnea--a review. Sleep. 2012;35(5):605-15.
30. Wells AS, Read NW, Idzikowski C, Jones J. Effects of meals on objective and subjective measures of daytime sleepiness. J Appl Physiol (1985). 1998;84(2):507-15.
31. Gutzwiller JP, Drewe J, Goke B, Schmidt H, Rohrer B, Lareida J, et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol. 1999;276(5 Pt 2):R1541-4.
32. van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond). 2014;38(6):784-93.
33. Inoue K, Maeda N, Kashine S, Fujishima Y, Kozawa J, Hiuge-Shimizu A, et al. Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes. Cardiovasc Diabetol. 2011;10:109.
34. The National Institute for Health and Care Excellence. Management of type-2 diabetes. 2009. https://www.nice.org.uk/guidance/ta203/resources/nice-recommendsliraglutide-for-type-2-diabetes-mellitus4. Accessed 17 Apr 2015.